AI for business development in biotech

Partnering is a memory job wearing a deal job's clothes. The expertise is not the bottleneck. The bottleneck is that what you learned on Tuesday's call has to still be true, and still findable, when the other side's diligence list lands on Thursday.

Most writing about AI in business development is about finding partners: scanning pipelines, scoring fit, building target lists. That is a real job and it is not this one. This page is about what happens after the first meeting, when a deal becomes a set of open threads with dates attached to them, and the person holding all of it is one VP with a laptop.

A biotech BD desk generates a specific kind of debris. A confidentiality agreement with an expiry. A diligence question list with a deadline that moves. Two term sheet versions and a redline. A data room index that is only accurate if someone updates it. A comp you quoted from memory in a board meeting and now cannot re-derive. A partner who has gone quiet for eleven days and you are not sure whether that is a signal or a holiday. None of that lives anywhere structurally. It lives in your inbox and your head.

What happens when the partner email lands

Take an ordinary one. The counterpart writes to say their internal committee slot moved up, so they need the round two answers two weeks earlier than agreed, same scope, no new questions. On a normal Tuesday that email gets read, mentally noted, and answered at nine that night, and the four things it silently changed do not get changed.

What a system built for this does instead is file the email into that deal on the next scheduled pass, move the answer date on the deal record, and move what depended on it: the data room loading schedule, the internal review slot that has to happen before the answers go out, and the note to yourself that your clinical and CMC leads now have less runway than they think. It closes the open item that this email resolves, opens the ones it creates, and writes a draft reply for you to approve or throw away. Nothing is sent without you saying so.

The point is not the drafting. The point is that one inbound email touched five records, and you touched none of them.

The promise nobody wrote down

The highest cost item on a BD desk is not the missed email. It is the verbal commitment. Somebody on a call says their legal team will have the redline back by the twenty third. You do not write it down, because it was said out loud and it felt obvious. The twenty seventh arrives and nothing has come in, and the reason you notice is that something downstream started to hurt.

A system that reads your meeting transcripts holds that promise as a dated open item against that person, sweeps every open promise on a schedule, and brings it back the morning it starts to cost you something, with the chasing note already drafted in your voice and in the context of what you have already exchanged with them. It also watches your sent mail, so the commitments you make going the other way get logged the same way, and the follow-up is diaried before the thread cools. All of it is single seat: your R&D lead owing you a safety package is captured as a thing for you to check on, never as a task, a reminder or an invitation sent to them.

That is the mechanism a customer relationship manager is supposed to provide and mostly does not, because a CRM only knows what somebody typed into it. The build or buy question for a biotech CRM turns almost entirely on this: the fields are not the hard part, the upkeep is. The same argument, aimed at the deal pipeline specifically, is on the deal tracking software page.

Which is why the useful question is not which partnering tool to buy. It is whether anything you own reads what already arrives. Nothing here sources deals or scores targets; it works on what you already receive and what you already say, and the argument for why that half is the half worth automating is on the drug development page. For a founder doing their own partnering, which at this company size is common, the closer framing is probably an AI chief of staff for a biotech founder: same machinery, wider brief, less deal-shaped. The rest of the function pages are in this section.